The effect of VLDL particles on the accuracy of a direct LDL-cholesterol method in type 2 diabetic patients

Clinical Biochemistry

Volumn 36, Issue 3, 2003, Pages 177-183

  Wägner, Ana María ^a   Zapico, Edgar ^a   Bonet, Rosa ^a   Pérez, Antonio ^a   Ordóñez Llanos, Jordi ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Direct method; IDL; LDL cholesterol; Type 2 diabetes mellitus; VLDL

Indexed keywords

INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SODIUM CHLORIDE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ACCURACY; ANALYTIC METHOD; ANALYTICAL ERROR; ARTICLE; CALCULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DILUTION; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICULATE MATTER; PHENOTYPE; PRIORITY JOURNAL; SAMPLE; SERUM; STANDARDIZATION; STATISTICAL SIGNIFICANCE; STEROL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0242500471     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(03)00006-7     Document Type: Article

References (34)

1. Management of dyslipidemia in adults with diabetes. Diabetes Care. 24:(suppl 1):2001;S58-S61.
2. Bachorik P.S., Ross J.W. National cholesterol education program recommendations for measurement of low-density lipoprotein cholesterol executive summary . Clin Chem. 41:1995;1414-1420.
3. Friedewald W.T., Levy R.J., Fredrickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
4. Rubies-Prat J., Reverter J.L., Senti M., et al. Calculated low-density lipoprotein cholesterol should not be used in the management of lipoprotein abnormalities in patients with diabetes mellitus. Diabetes Care. 16:1993;1081-1086.
5. Hirany S., Li K., Jialal I. A more valid measurement of low-density lipoprotein cholesterol in diabetic patients. Am J Med. 102:1997;48-53.
6. Branchi A., Rovellini A., Torri A., Sommariva D. Accuracy of calculated serum low-density lipoprotein cholesterol for the assessment of coronary heart disease risk in NIDDM patients. Diabetes Care. 21:1998;1397-1402.
7. Sentí M., Pedro-Botet J., Nogués X., Rubíes-Prat J. Influence of intermediate-density lipoproteins on the accuracy of the Friedewald formula. Clin Chem. 37:1991;1394-1397.
8. Wägner A.M., Sánchez-Quesada J.L., Pérez A., Rigla M., Blanco-Vaca F., Ordóñez-Llanos J. Inaccuracy of calculated LDL cholesterol in type 2 diabetes consequences for patient risk classification and therapeutic decision . Clin Chem. 46:2000;1830-1832.
9. Planella T., Cortés M., Martínez-Brú C., González-Sastre F., Ordóñez-Llanos J. Calculation of LDL cholesterol using apolipoprotein B for the phenotypical classification of non-chylomicronæmic dyslipæmia. Clin Chem. 43:1997;808-815.
10. Nauck M., Warnick G.R., Rifai N. Methods for measurement of LDL-cholesterol a critical assessment of direct measurement by homogeneous assays versus calculation . Clin Chem. 48:2002;236-254.
11. Whiting M.J., Shephard M.D.S., Tallis G.A. Measurement of plasma LDL cholesterol in patients with diabetes. Diabetes Care. 20:1997;12-14.
12. Ragland B.D., Konrad R.J., Chaffin C., Robinson C.A., Hardy R.W. Evaluation of a homogeneous direct LDL-cholesterol assay in diabetic patients effect of glycemic control . Clin Chem. 46:2000;1848-1851.
13. Nauck M., Graziani M.S., Bruton D., et al. Analytical and clinical performance of a detergent-based homogeneous LDL-cholesterol assay a multicenter evaluation . Clin Chem. 46:2000;506-514.
14. Ordóñez-Llanos J., Wägner A.M., Bonet-Marqués R., Sánchez-Quesada J.L., Blanco-Vaca F., González-Sastre F. Which cholesterol are we measuring with the Roche direct, homogeneous LDL-C Plus assay? Clin Chem. 47:2001;124-126.
15. Lipid Research Clinic Program. Manual of laboratory operations, lipid and lipoprotein analysis. In: Hainline A, Karon J, Lippel K, editors. National Heart, Lung and Blood Institute, Bethesda, MD 20205 (US Government Printing Office No. 1982-36 1-132:678). (1982) HEW Publication No. (NIH): 75 (revised).
16. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. i:1986;307-310.
17. Miller W.G., Waymack P.P., Anderson F.P., Ethridge S.F., Jayne E.C. Performance of four homogeneous direct methods for LDL-cholesterol. Clin Chem. 48:2002;489-498.
18. Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
19. Dewitte K., Fierens C., Stockl D., Thienpont L.M. Application of the Bland-Altman plot for interpretation of method-comparison studies a critical investigation of its practice . Clin Chem. 48:2002;799-801.
20. Haffner S.M. Management of dyslipidemia in adults with diabetes. Diabetes Care. 21:1998;160-178.
21. Watanabe N., Taniguchi T., Taketoh H., et al. Elevated remnant-like lipoproteins particles in impaired glucose tolerance and type 2 diabetic patients. Diabetes Care. 22:1999;152-156.
22. McNamara J., Cohn J.S., Wilson P.W.F., Schaefer E.J. Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. Clin Chem. 36:1990;36-42.
23. Warnick G.R. Lack of agreement of homogeneous assays with the reference method for LDL-cholesterol may not indicate unrealiaable prediction of risk for cardiovascular disease. Clin Chem. 48:2002;1812-1814.
24. Fei H., Maeda S., Kirii H. Evaluation of two different homogeneous assays for LDL-cholesterol in lipoprotein-X-positive serum. Clin Chem. 46:2000;1351-1356.
25. Sakaue T., Hirano T., Hoshino G., Sakai K., Takeuchi H., Adachi M. Reactions of direct LDL-cholesterol assays with pure LDL fraction and IDL comparison of three homogeneous methods . Clin Chim Acta. 295:2000;97-106.
26. Usui S., Kakuuchi H., Kamoto M., Mizuka Y., Okazaki M. Differential reactivity of two homogeneous LDL-cholesterol methods to LDL and VLDL subfractions, as demonstrated by ultracentrifugation and HPLC. Clin Chem. 48:2002;1946-1954.
27. Caixàs A., Ordóñez-Llanos J., de Leiva A., Payés A., Homs R., Pérez A. Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients. Diabetes. 46:1997;1207-1213.
28. Scharnagl H., Nauck M., Wiedland H., März W. The Friedewald formula underestimates LDL cholesterol at low concentrations. Clin Chem Lab Med. 39:2001;426-431.
29. Nauck M., Rifai N. Analytical performance and clinical efficacy of three routine procedures for LDL cholesterol measurement compared with the ultracentrifugation-dextran sulfate-Mg (2+) method. Clin Chim Acta. 294:2000;77-92.
30. Wägner A.M., Peña C., Jorba O. Repercusiones clínicas de la fórmula de Friedewald para el cálculo del colesterol de LDL utilizando los puntos de corte establecidos por el NCEP. Clin Invest Arteriosclerosis. 12:2000;160-166.
31. Gotto A.M., Whitney E., Stein E.A., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 101:2000;477-484.
32. Van Lennep J.E., Westerveld H.T., van Lennep H.W., Zwinderman A.H., Erkelens D.W., van Der Wall E.E. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol. 20:2000;2408-2413.
33. Sniderman A.D., Lamarche B., Tilley J., Seccombe D., Frohlich J. Hypertriglyceridemic hyperapo(B) in type 2 diabetes. Diabetes Care. 25:2002;579-582.
34. Wägner A.M., Pérez A., Calvo F., Bonet R., Castellví A., Ordóñez J. Apolipoprotein B identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients. Diabetes Care. 22:1999;812-817.